SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2016 / Cilt: 7 - Sayı: 1

Kronik Hepatit C Tedavisi Sırasında Alfa-Feto Protein Düzeylerindeki Seri Değişiklikler

Serial Changes in Alpha-Fetoprotein Levels During Therapy for Chronic Hepatitis C

Mete AKIN
Yıldıran SONGÜR
M Cem KOÇKAR
Mehmet İŞLER
Altuğ ŞENOL
Pages
23–26
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In these patients, mean serum AFP levels were decreased from pretreatment level of 15,09 ± 5,92 ng/ml to 11,39±3,30, to 6,97±2,53 (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Alpha-fetoprotein (AFP) has been widely used as a diagnostic marker for hepatocellular carcinoma.
📊
Key Findings & Data:Material and Method: Thirty seven chronic hepatitis C patients (20 females and 17 males) were included in the study.
💡
Conclusion & Impact:In these patients, mean serum AFP levels were decreased from pretreatment level of 15,09 ± 5,92 ng/ml to 11,39±3,30, to 6,97±2,53 (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Alpha-fetoprotein (AFP) has been widely used as a diagnostic marker for hepatocellular carcinoma. Some patients with hepatitis C show high AFP values, but no evidence of hepatocellular carcinoma. The aim of this study is to assess the influence of antiviral treatment on the serum AFP in patients with chronic hepatitis C without hepatocellular carcinoma. Material and Method: Thirty seven chronic hepatitis C patients (20 females and 17 males) were included in the study. All patients were given a combined treatment of pegylated or conventional interferon (IFN) and ribavirin. Serum AFP was measured at baseline and on months 3-6-12 of the therapy. Results: Compared to the pretreatment levels of ALT (88,59 ± 57,22 IU), those at 3, 6 and 12 months were statistically lower (p 0,05), to 4,34 ± 4,64 (p>0,05) and to 2,63 ± 2,17 (p10 ng/ml). In these patients, mean serum AFP levels were decreased from pretreatment level of 15,09 ± 5,92 ng/ml to 11,39±3,30, to 6,97±2,53 (p

Özet

Amaç: Alfa-feto protein (AFP) hepatosellüler karsinom tanısı için yaygın olarak kullanılan bir belirteçtir. Bazı hepatit C'li hastalar, yüksek AFP değerleri sergilemekte ancak hepatosellüler karsinom kanıtı bulundurmamaktadırlar. Bu çalışmanın amacı, hepatosellüler karsinomu bulunmayan kronik hepatit C'li hastalarda serum AFP üzerinde antiviral tedavinin etkisini değerlendirmektir. Gereç ve Yöntem: Kronik hepatit C'li otuz yedi hasta (20 kadın ve 17 erkek) bu çalışmaya dahil edildi. Tüm hastalara pegile veya konvansiyonel IFN ve ribavirin kombinasyon tedavisi verildi. Serum AFP bazal değerde ve tedavinin 3-6-12. aylarında ölçüldü. Bulgular: ALT düzeyinin tedavi öncesi ile karşılaştırıldığında (88,59 ± 57.22 IU) 3,6 ve 12. aylardaki düzeyleri istatistiksel olarak daha düşüktü (p 0,05), 6. ayda 4,34 ± 4,64 (p>0,05) ve 12. ayda 2,63 ± 2,17 (p10 ng/ml) 3. ayda istatistiksel olarak anlamlı olmayan düşme gözlenirken; 6. ve 12. aylarda istatistiksel olarak anlamlı oranda düşüş gözlendi. Bu hastalarda ortalama serum AFP düzeyleri 3, 6 ve 12. aylarda sırasıyla 11,39±3,30, 6,97±2,53 (p

🔖

Cite This Article

AKIN, M., SONGÜR, Y., KOÇKAR, M. C., İŞLER, M., ŞENOL, A. (2022). Kronik Hepatit C Tedavisi Sırasında Alfa-Feto Protein Düzeylerindeki Seri Değişiklikler. Journal of Clinical and Analytical Medicine, Cilt: 7 - Sayı: 1, 23–26. https://ajindex.com/articles/560910

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion- associated hepatitis C. N Engl J Med 1995;332(22): 1463-6.
  2. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000;132(4):296-305.
  3. Hino K, Okita K. Interferon therapy as chemoprevention of hepatocarcinogene- sis in patients with chronic hepatitis C. J Antimicrob Chemother 2004;53(1):19-22.
  4. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med;339(21):1485-92.
  5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet;358(9286):958-65.
  6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Pe- ginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82.
  7. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chro- nic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepa- tol 2006;44(1):97-103.
  8. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Ran- domised trial of effects of interferon-alpha on incidence of hepatocellular carci- noma in chronic active hepatitis C with cirrhosis. Lancet 1995;346(8982):1051-5.
  9. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha inter- feron treatment may prevent hepatocellular carcinoma in HCV-related liver cirrho- sis. J Hepatol 1996;24(2):141-7.
  10. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology;28(4):1121-7.
  11. Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, et al. Inter- feron retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 2002;9(5):370-6.
  12. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocel- lular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastro- enterol 2003;237(Suppl.):S47-51. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S,